Table 2.
Demographics and characteristics of the study population (N = 537).
| Variable | Overall (n = 537) | HIV-1 subtypes | p-Value | ||||
|---|---|---|---|---|---|---|---|
| CRF01_AE (n = 312) | CRF07_BC (n = 153) | CRF08_BC (n = 38) | CRF55_01B (n = 19) | B (n = 15) | |||
| Age, median (IQR), y | 42 (35, 50.5) | 42 (35.25, 53) | 43 (35, 49) | 40 (34, 47) | 39 (32, 49) | 42 (37, 47) | 0.4200 |
| Gender, n (%) | 0.0899 | ||||||
| Male | 414 (77.1) | 233 (74.7) | 121 (79.1) | 28 (73.7) | 19 (100.0) | 13 (86.7) | |
| Female | 123 (22.9) | 79 (25.3) | 32 (20.9) | 10 (26.3) | 0 | 2 (13.3) | |
| Delay of HAART initiation, median (IQR), d | 77 (23, 706) | 68 (23.25, 489) | 239 (26.5, 1,464) | 93 (33.75, 251.75) | 23 (15, 72) | 50 (8,953) | 0.0006 |
| Time on HAART, median (IQR), d | 1,017 (496, 1,777.5) | 1122.5 (620.5, 1,995) | 835 (431.5, 1,480.5) | 854 (295.5, 2,028.25) | 448 (321, 1,036) | 898 (440, 1,474) | <0.0001 |
| Plasma HIV-1 RNA (copies/mL), median (IQR) | 642 (508.5, 782.5) | 614.5 (492, 765.5) | 679 (540.25, 836.5) | 651.5 (480.5, 741.75) | 683 (588, 837) | 549 (454, 726) | 0.0527 |
| Initial HAART regimen prescribed, n (%) | 0.1576 | ||||||
| NRTIs + NNRTIs | 475 (88.5) | 268 (85.9) | 141 (92.2) | 34 (89.5) | 19 (100.0) | 13 (86.7) | |
| Others | 62 (11.5) | 44 (14.1) | 12 (7.8) | 4 (10.5) | 0 | 2 (13.3) | |
| Routes of infection, n (%) | 0.0012 | ||||||
| Sexual transmission | 296 (55.1) | 180 (57.7) | 73 (47.7) | 17 (44.7) | 15 (78.9) | 11 (73.3) | |
| Non sexual transmission | 200 (37.2) | 108 (34.6) | 71 (46.4) | 19 (50.0) | 1 (5.3) | 1 (6.7) | |
| N/A | 41 (7.6) | 24 (7.7) | 9 (5.9) | 2 (5.3) | 3 (15.8) | 3 (20.0) | |
| In-silico predictions of HIV-1 co-receptor usage, n (%) | <0.0001 | ||||||
| CCR5-using | 413 (76.9) | 207 (66.3) | 147 (96.1) | 37 (97.4) | 10 (52.6) | 12 (80.0) | |
| CXCR4-using | 124 (23.1) | 105 (33.7) | 6 (3.9) | 1 (2.6) | 9 (47.4) | 3 (20.0) | |
Data are presented as no. (%).
HAART, Highly active antiretroviral therapy; NRTIs, Nucleoside reverse transcriptase inhibitors; NNRTIs, Non-nucleoside reverse transcriptase inhibitors.